Loading page content…
Novartis AG
BullApe has not made a call on NVS yet. The articles below discuss it.
Members see why each call was made, which sources drove it, the price chart with every call marked, earnings, and what finance YouTubers and X accounts are saying.
Novartis just had the worst week in pharma since 2020. Three trial failures, a $12B acquisition that's looking like a dud, and analysts quietly giving up on the growth story.
See how every BullApe call is graded. Research, not financial advice.